A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from <scp>CALGB</scp> 40502 (Alliance)
Sara R. Rashkin(University of California, San Francisco), Deanna L. Kroetz(University of California, San Francisco), Kouros Owzar(Duke University), John S. Witte(University of California, San Francisco), Deborah Toppmeyer(Rutgers, The State University of New Jersey), Katherina C. Chua(University of California, San Francisco), Flora Mulkey(Sherwin Williams (United States)), Francisco Castillos(Nash Community College), Mark J. Ratain(University of Chicago), Michiaki Kubo(RIKEN Center for Integrative Medical Sciences), Beth Overmoyer(Harvard University), Michael Naughton(Boston College), Tasei Mushiroda(RIKEN Center for Integrative Medical Sciences), Hope S. Rugo(City of Hope), Chen Jiang, Howard L. McLeod(Unknown), Paula N. Friedman(University of North Carolina at Chapel Hill), Carol Ho(University of California, San Francisco)
Cited by 13
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k